BACKGROUND Rebleeding after recovery from esophagogastric variceal bleeding(EGVB)is a severe complication that is associated with high rates of both incidence and mortality.Despite its clinical importance,recognized p...BACKGROUND Rebleeding after recovery from esophagogastric variceal bleeding(EGVB)is a severe complication that is associated with high rates of both incidence and mortality.Despite its clinical importance,recognized prognostic models that can effectively predict esophagogastric variceal rebleeding in patients with liver cirrhosis are lacking.AIM To construct and externally validate a reliable prognostic model for predicting the occurrence of esophagogastric variceal rebleeding.METHODS This study included 477 EGVB patients across 2 cohorts:The derivation cohort(n=322)and the validation cohort(n=155).The primary outcome was rebleeding events within 1 year.The least absolute shrinkage and selection operator was applied for predictor selection,and multivariate Cox regression analysis was used to construct the prognostic model.Internal validation was performed with bootstrap resampling.We assessed the discrimination,calibration and accuracy of the model,and performed patient risk stratification.RESULTS Six predictors,including albumin and aspartate aminotransferase concentrations,white blood cell count,and the presence of ascites,portal vein thrombosis,and bleeding signs,were selected for the rebleeding event prediction following endoscopic treatment(REPET)model.In predicting rebleeding within 1 year,the REPET model ex-hibited a concordance index of 0.775 and a Brier score of 0.143 in the derivation cohort,alongside 0.862 and 0.127 in the validation cohort.Furthermore,the REPET model revealed a significant difference in rebleeding rates(P<0.01)between low-risk patients and intermediate-to high-risk patients in both cohorts.CONCLUSION We constructed and validated a new prognostic model for variceal rebleeding with excellent predictive per-formance,which will improve the clinical management of rebleeding in EGVB patients.展开更多
A multicenter study recently published introduced a novel prognostic model for predicting esophagogastric variceal rebleeding after endoscopic treatment in patients with cirrhosis.The model incorporated six readily av...A multicenter study recently published introduced a novel prognostic model for predicting esophagogastric variceal rebleeding after endoscopic treatment in patients with cirrhosis.The model incorporated six readily available clinical variables—albumin level,aspartate aminotransferase level,white blood cell count,ascites,portal vein thrombosis,and bleeding signs—and demonstrated promising predictive performance.However,limitations,including the retrospective design and exclusion of patients with hepatocellular carcinoma,may affect the generaliz-ability of the model.Additionally,further improvement is needed in the model’s discrimination between intermediate-and high-risk groups in external.Prospec-tive validation and inclusion of additional variables are recommended to enhan-ce predictive accuracy across diverse clinical scenarios.展开更多
AIM: To systematically assess the efficacy and safety of β-adrenergic blocker plus 5-isosorbide mononitrate (BB + ISMN) and endoscopic band ligation (EBL) on prophylaxis of esophageal variceal rebleeding. METHODS: Ra...AIM: To systematically assess the efficacy and safety of β-adrenergic blocker plus 5-isosorbide mononitrate (BB + ISMN) and endoscopic band ligation (EBL) on prophylaxis of esophageal variceal rebleeding. METHODS: Randomized controlled trials (RCTs) comparing the efficacy and safety of BB + ISMN and EBL on prophylaxis of esophageal variceal rebleeding were gathered from Medline, Embase, Cochrane Controlled Trial Registry and China Biological Medicine database between January 1980 and August 2007. Data from five trials were extracted and pooled. The analyses of the available data using the Revman 4.2 software were based on the intention-to-treat principle. RESULTS: Four RCTs met the inclusion criteria. In comparison with BB + ISMN with EBL in prophylaxis of esophageal variceal rebleeding, there was no significant difference in the rate of rebleeding [relative risk (RR), 0.79; 95% CI: 0.62-1.00; P = 0.05], bleeding-related mortality (RR, 0.76; 95% CI: 0.31-1.42; P = 0.40), overall mortality (RR, 0.81; 95% CI: 0.61-1.08; P = 0.15) and complications (RR, 1.26; 95% CI: 0.93-1.70; P = 0.13). CONCLUSION:In the prevention of esophageal variceal rebleeding, BB + ISMN are as effective as EBL. There are few complications with the two treatment modalities. Both BB + ISMN and EBL would be considered as the first-line therapy in the prevention of esophageal variceal rebleeding.展开更多
Objective To assess whether adjuvant Chinese patent medicines(CPMs)to standard treatment could reduce recurrent bleeding after variceal bleeding in cirrhotic patients.Methods This study retrospectively collected 555 c...Objective To assess whether adjuvant Chinese patent medicines(CPMs)to standard treatment could reduce recurrent bleeding after variceal bleeding in cirrhotic patients.Methods This study retrospectively collected 555 consecutive patients who recovered from variceal bleeding.A population-based cohort study was established depending on if adjuvant CPMs were administered to prevent rebleeding.A total of 139 patients who had taken⩾28 cumulative defined daily doses(cDDDs)of CPMs were included in the CPMs cohort,and 416 patients who used<28 cDDDs of CPMs were enrolled in the non-CPMs cohort.On evaluation of rebleeding incidence,1:2 propensity score matched was used to estimate for reducing bias.Patients were followed for at least 12 months.The end-point of this study was clinically significant esophagogastric variceal rebleeding.Results Following multivariate analysis,CPMs therapy was an independent factor for variceal rebleeding[adjusted hazard ratio(AHR)=0.657;95%confidence interval=0.497-0.868;P=0.003].After the 1:2 propensity score matching,a significant reduction(23.5%)in the incidence of variceal rebleeding in patients was observed,from 58.3%in the non-CPMs cohort to 44.6%in the CPMs cohort(modified log-rank test,P=0.002)within a year.The AHRs for rebleeding were 0.928,0.553,and 0.105,for 28-90 cDDDs,91-180 cDDDs,and>180 cDDDs of CPMs,respectively.The median rebleeding interval in the CPMs cohort was significantly larger compared with the non-CPMs cohort(113.5 vs.93.0 days;P=0.008).Conclusion Adjuvant CPMs to standard therapy can significantly reduce the incidence of variceal rebleeding and delay the time to rebleeding.展开更多
Background: Treatment options for patients with cavernous transformation of portal vein(CTPV) are limited. This study aimed to evaluate the feasibility, efficacy and safety of transjugular intrahepatic portosystemic s...Background: Treatment options for patients with cavernous transformation of portal vein(CTPV) are limited. This study aimed to evaluate the feasibility, efficacy and safety of transjugular intrahepatic portosystemic shunt(TIPS) to prevent recurrent esophageal variceal bleeding in patients with CTPV. Methods: We retrospectively analyzed 67 consecutive patients undergone TIPS from January 2011 to December 2016. All patients were diagnosed with CTPV. The indication for TIPS was a previous episode of variceal bleeding. The data on recurrent bleeding, stent patency, hepatic encephalopathy and survival were retrieved and analyzed. Results: TIPS procedure was successfully performed in 56 out of 67(83.6%) patients with CTPV. TIPS was performed via a transjugular approach alone( n = 15), a combined transjugular/transhepatic approach( n = 33) and a combined transjugular/transsplenic approach( n = 8). Mean portosystemic pressure gradient(PSG) decreased from 28.09 ± 7.28 mmHg to 17.53 ± 6.12 mmHg after TIPS( P < 0.01). The probability of the remaining free recurrent variceal bleeding was 87.0%. The probability of TIPS patency reached 81.5%. Hepatic encephalopathy occurrence was 27.8%, and survival rate was 88.9% until the end of follow-up. Four out of 11 patients who failed TIPS died, and 4 had recurrent bleeding. Conclusions: TIPS should be considered a safe and feasible alternative therapy to prevent recurrent esophageal variceal bleeding in patients with CTPV, and to achieve clinical improvement.展开更多
BACKGROUND It is controversial whether transjugular intrahepatic portosystemic shunt(TIPS)placement can improve long-term survival.AIM To assess whether TIPS placement improves survival in patients with hepaticvenous-...BACKGROUND It is controversial whether transjugular intrahepatic portosystemic shunt(TIPS)placement can improve long-term survival.AIM To assess whether TIPS placement improves survival in patients with hepaticvenous-pressure-gradient(HVPG)≥16 mmHg,based on HVPG-related risk stratification.METHODS Consecutive variceal bleeding patients treated with endoscopic therapy+nonselectiveβ-blockers(NSBBs)or covered TIPS placement were retrospectively enrolled between January 2013 and December 2019.HVPG measurements were performed before therapy.The primary outcome was transplant-free survival;secondary endpoints were rebleeding and overt hepatic ence-phalopathy(OHE).RESULTS A total of 184 patients were analyzed(mean age,55.27 years±13.86,107 males;102 in the EVL+NSBB group,82 in the covered TIPS group).Based on the HVPG guided risk stratification,70 patients had HVPG<16 mmHg,and 114 patients had HVPG≥16 mmHg.The median follow-up time of the cohort was 49.5 mo.There was no significant difference in transplant-free survival between the two treatment groups overall(hazard ratio[HR],0.61;95%confidence interval[CI]:0.35-1.05;P=0.07).In the high-HVPG tier,transplant-free survival was higher in the TIPS group(HR,0.44;95%CI:0.23-0.85;P=0.004).In the low-HVPG tier,transplantfree survival after the two treatments was similar(HR,0.86;95%CI:0.33-0.23;P=0.74).Covered TIPS placement decreased the rate of rebleeding independent of the HVPG tier(P<0.001).The difference in OHE between the two groups was not statistically significant(P=0.09;P=0.48).CONCLUSION TIPS placement can effectively improve transplant-free survival when the HVPG is greater than 16 mmHg.展开更多
Background:Portosystemic shunts,including surgical portosystemic shunts and transjugular intra-hepatic portosystemic shunt(TIPS),may have benefit over endoscopic therapy(ET)for treatment of variceal bleeding in patien...Background:Portosystemic shunts,including surgical portosystemic shunts and transjugular intra-hepatic portosystemic shunt(TIPS),may have benefit over endoscopic therapy(ET)for treatment of variceal bleeding in patients with cirrhotic portal hypertension;however,whether there being a survival benefit among them remains unclear.This study was to compare the effect of three above-mentioned therapies on the short-term and long-term survival in patient with cirrhosis.Methods:Using the terms"variceal hemorrhage or variceal bleeding or variceal re-bleeding"OR"esophageal and gastric varices"OR"portal hypertension"and"liver cirrhosis,"the Cochrane Central Register of Controlled Trials,PubMed,Embase,and the references of identified trials were searched for human randomized controlled trials(RCTs)published in any language with full texts or abstracts(last search June 2017).Risk ratio(RR)estimates with 95%confidence interval(CI)were calculated using random effects model by Review Manager.The quality of the included studies was evaluated using the Cochrane Collaboration’s tool for the assessment of the risk of bias.Results:Twenty-six publications comprising 28 RCTs were included in this analysis.These studies included a total of 2845 patients:496(4 RCTs)underwent either surgical portosystemic shunts or TIPS,1244(9 RCTs)underwent either surgical portosystemic shunts or ET,and 1105(15 RCTs)underwent either TIPS or ET.There was no significant difference in overall mortality and 30-day or 6-week survival among three interventions.Compared with TIPS and ET,separately,surgical portosystemic shunts were both associated with a lower bleeding-related mortality(RR=0.07,95%CI=0.01–0.32;P<0.001;RR=0.17,95%CI=0.06–0.51,P<0.005)and rate of variceal re-bleeding(RR=0.23,95%CI=0.10–0.51,P<0.001;RR=0.10,95%CI=0.04–0.24,P<0.001),without a significant difference in the rate of postoperative hepatic encephalopathy(RR=0.52,95%CI=0.25–1.00,P=0.14;RR=1.09,95%CI=0.59–2.01,P=0.78).TIPS showed a trend toward lower variceal re-bleeding(RR=0.46,95%CI=0.36–0.58,P<0.001),but a higher incidence of hepatic encephalopathy than ET(RR=1.78,95%CI=1.34–2.36,P<0.001).Conclusions:The overall analysis revealed that there seem to be no short-term and long-term survival advantage,but surgical portosystemic shunts are with the lowest bleeding-related mortality among the three therapies.Surgical portosystemic shunts may be the most effective without an increased risk of hepatic encephalopathy and TIPS is superior to ET but at the cost of a higher incidence of hepatic encephalopathy.However,some of findings should be interpreted with caution due to the lower level of evidence and the existence of significant heterogeneity.展开更多
基金Supported by National Natural Science Foundation of China,No.81874390 and No.81573948Shanghai Natural Science Foundation,No.21ZR1464100+1 种基金Science and Technology Innovation Action Plan of Shanghai Science and Technology Commission,No.22S11901700the Shanghai Key Specialty of Traditional Chinese Clinical Medicine,No.shslczdzk01201.
文摘BACKGROUND Rebleeding after recovery from esophagogastric variceal bleeding(EGVB)is a severe complication that is associated with high rates of both incidence and mortality.Despite its clinical importance,recognized prognostic models that can effectively predict esophagogastric variceal rebleeding in patients with liver cirrhosis are lacking.AIM To construct and externally validate a reliable prognostic model for predicting the occurrence of esophagogastric variceal rebleeding.METHODS This study included 477 EGVB patients across 2 cohorts:The derivation cohort(n=322)and the validation cohort(n=155).The primary outcome was rebleeding events within 1 year.The least absolute shrinkage and selection operator was applied for predictor selection,and multivariate Cox regression analysis was used to construct the prognostic model.Internal validation was performed with bootstrap resampling.We assessed the discrimination,calibration and accuracy of the model,and performed patient risk stratification.RESULTS Six predictors,including albumin and aspartate aminotransferase concentrations,white blood cell count,and the presence of ascites,portal vein thrombosis,and bleeding signs,were selected for the rebleeding event prediction following endoscopic treatment(REPET)model.In predicting rebleeding within 1 year,the REPET model ex-hibited a concordance index of 0.775 and a Brier score of 0.143 in the derivation cohort,alongside 0.862 and 0.127 in the validation cohort.Furthermore,the REPET model revealed a significant difference in rebleeding rates(P<0.01)between low-risk patients and intermediate-to high-risk patients in both cohorts.CONCLUSION We constructed and validated a new prognostic model for variceal rebleeding with excellent predictive per-formance,which will improve the clinical management of rebleeding in EGVB patients.
文摘A multicenter study recently published introduced a novel prognostic model for predicting esophagogastric variceal rebleeding after endoscopic treatment in patients with cirrhosis.The model incorporated six readily available clinical variables—albumin level,aspartate aminotransferase level,white blood cell count,ascites,portal vein thrombosis,and bleeding signs—and demonstrated promising predictive performance.However,limitations,including the retrospective design and exclusion of patients with hepatocellular carcinoma,may affect the generaliz-ability of the model.Additionally,further improvement is needed in the model’s discrimination between intermediate-and high-risk groups in external.Prospec-tive validation and inclusion of additional variables are recommended to enhan-ce predictive accuracy across diverse clinical scenarios.
文摘AIM: To systematically assess the efficacy and safety of β-adrenergic blocker plus 5-isosorbide mononitrate (BB + ISMN) and endoscopic band ligation (EBL) on prophylaxis of esophageal variceal rebleeding. METHODS: Randomized controlled trials (RCTs) comparing the efficacy and safety of BB + ISMN and EBL on prophylaxis of esophageal variceal rebleeding were gathered from Medline, Embase, Cochrane Controlled Trial Registry and China Biological Medicine database between January 1980 and August 2007. Data from five trials were extracted and pooled. The analyses of the available data using the Revman 4.2 software were based on the intention-to-treat principle. RESULTS: Four RCTs met the inclusion criteria. In comparison with BB + ISMN with EBL in prophylaxis of esophageal variceal rebleeding, there was no significant difference in the rate of rebleeding [relative risk (RR), 0.79; 95% CI: 0.62-1.00; P = 0.05], bleeding-related mortality (RR, 0.76; 95% CI: 0.31-1.42; P = 0.40), overall mortality (RR, 0.81; 95% CI: 0.61-1.08; P = 0.15) and complications (RR, 1.26; 95% CI: 0.93-1.70; P = 0.13). CONCLUSION:In the prevention of esophageal variceal rebleeding, BB + ISMN are as effective as EBL. There are few complications with the two treatment modalities. Both BB + ISMN and EBL would be considered as the first-line therapy in the prevention of esophageal variceal rebleeding.
基金Supported by the Capital Health Development Research Project(No.2018-1-2172)Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding(No.ZYLX201707)。
文摘Objective To assess whether adjuvant Chinese patent medicines(CPMs)to standard treatment could reduce recurrent bleeding after variceal bleeding in cirrhotic patients.Methods This study retrospectively collected 555 consecutive patients who recovered from variceal bleeding.A population-based cohort study was established depending on if adjuvant CPMs were administered to prevent rebleeding.A total of 139 patients who had taken⩾28 cumulative defined daily doses(cDDDs)of CPMs were included in the CPMs cohort,and 416 patients who used<28 cDDDs of CPMs were enrolled in the non-CPMs cohort.On evaluation of rebleeding incidence,1:2 propensity score matched was used to estimate for reducing bias.Patients were followed for at least 12 months.The end-point of this study was clinically significant esophagogastric variceal rebleeding.Results Following multivariate analysis,CPMs therapy was an independent factor for variceal rebleeding[adjusted hazard ratio(AHR)=0.657;95%confidence interval=0.497-0.868;P=0.003].After the 1:2 propensity score matching,a significant reduction(23.5%)in the incidence of variceal rebleeding in patients was observed,from 58.3%in the non-CPMs cohort to 44.6%in the CPMs cohort(modified log-rank test,P=0.002)within a year.The AHRs for rebleeding were 0.928,0.553,and 0.105,for 28-90 cDDDs,91-180 cDDDs,and>180 cDDDs of CPMs,respectively.The median rebleeding interval in the CPMs cohort was significantly larger compared with the non-CPMs cohort(113.5 vs.93.0 days;P=0.008).Conclusion Adjuvant CPMs to standard therapy can significantly reduce the incidence of variceal rebleeding and delay the time to rebleeding.
文摘Background: Treatment options for patients with cavernous transformation of portal vein(CTPV) are limited. This study aimed to evaluate the feasibility, efficacy and safety of transjugular intrahepatic portosystemic shunt(TIPS) to prevent recurrent esophageal variceal bleeding in patients with CTPV. Methods: We retrospectively analyzed 67 consecutive patients undergone TIPS from January 2011 to December 2016. All patients were diagnosed with CTPV. The indication for TIPS was a previous episode of variceal bleeding. The data on recurrent bleeding, stent patency, hepatic encephalopathy and survival were retrieved and analyzed. Results: TIPS procedure was successfully performed in 56 out of 67(83.6%) patients with CTPV. TIPS was performed via a transjugular approach alone( n = 15), a combined transjugular/transhepatic approach( n = 33) and a combined transjugular/transsplenic approach( n = 8). Mean portosystemic pressure gradient(PSG) decreased from 28.09 ± 7.28 mmHg to 17.53 ± 6.12 mmHg after TIPS( P < 0.01). The probability of the remaining free recurrent variceal bleeding was 87.0%. The probability of TIPS patency reached 81.5%. Hepatic encephalopathy occurrence was 27.8%, and survival rate was 88.9% until the end of follow-up. Four out of 11 patients who failed TIPS died, and 4 had recurrent bleeding. Conclusions: TIPS should be considered a safe and feasible alternative therapy to prevent recurrent esophageal variceal bleeding in patients with CTPV, and to achieve clinical improvement.
基金Supported by the National Natural Science Foundation of China,No.81900552Nanjing Health Science,Technology Development Special Fund Project-Key project,No.ZKX19015+1 种基金Outstanding Youth Fund project,No.JQX20005Funding for Clinical Trials from the Affiliated Drum Tower Hospital,Medical School of Nanjing University,No.2022-LCYJ-MS-13.
文摘BACKGROUND It is controversial whether transjugular intrahepatic portosystemic shunt(TIPS)placement can improve long-term survival.AIM To assess whether TIPS placement improves survival in patients with hepaticvenous-pressure-gradient(HVPG)≥16 mmHg,based on HVPG-related risk stratification.METHODS Consecutive variceal bleeding patients treated with endoscopic therapy+nonselectiveβ-blockers(NSBBs)or covered TIPS placement were retrospectively enrolled between January 2013 and December 2019.HVPG measurements were performed before therapy.The primary outcome was transplant-free survival;secondary endpoints were rebleeding and overt hepatic ence-phalopathy(OHE).RESULTS A total of 184 patients were analyzed(mean age,55.27 years±13.86,107 males;102 in the EVL+NSBB group,82 in the covered TIPS group).Based on the HVPG guided risk stratification,70 patients had HVPG<16 mmHg,and 114 patients had HVPG≥16 mmHg.The median follow-up time of the cohort was 49.5 mo.There was no significant difference in transplant-free survival between the two treatment groups overall(hazard ratio[HR],0.61;95%confidence interval[CI]:0.35-1.05;P=0.07).In the high-HVPG tier,transplant-free survival was higher in the TIPS group(HR,0.44;95%CI:0.23-0.85;P=0.004).In the low-HVPG tier,transplantfree survival after the two treatments was similar(HR,0.86;95%CI:0.33-0.23;P=0.74).Covered TIPS placement decreased the rate of rebleeding independent of the HVPG tier(P<0.001).The difference in OHE between the two groups was not statistically significant(P=0.09;P=0.48).CONCLUSION TIPS placement can effectively improve transplant-free survival when the HVPG is greater than 16 mmHg.
基金supported by grants from the Beijing Municipal Administration of Hospitals Ascent Plan(No.DFL20150101)Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Fundi昭Support(No.XMLX201815).
文摘Background:Portosystemic shunts,including surgical portosystemic shunts and transjugular intra-hepatic portosystemic shunt(TIPS),may have benefit over endoscopic therapy(ET)for treatment of variceal bleeding in patients with cirrhotic portal hypertension;however,whether there being a survival benefit among them remains unclear.This study was to compare the effect of three above-mentioned therapies on the short-term and long-term survival in patient with cirrhosis.Methods:Using the terms"variceal hemorrhage or variceal bleeding or variceal re-bleeding"OR"esophageal and gastric varices"OR"portal hypertension"and"liver cirrhosis,"the Cochrane Central Register of Controlled Trials,PubMed,Embase,and the references of identified trials were searched for human randomized controlled trials(RCTs)published in any language with full texts or abstracts(last search June 2017).Risk ratio(RR)estimates with 95%confidence interval(CI)were calculated using random effects model by Review Manager.The quality of the included studies was evaluated using the Cochrane Collaboration’s tool for the assessment of the risk of bias.Results:Twenty-six publications comprising 28 RCTs were included in this analysis.These studies included a total of 2845 patients:496(4 RCTs)underwent either surgical portosystemic shunts or TIPS,1244(9 RCTs)underwent either surgical portosystemic shunts or ET,and 1105(15 RCTs)underwent either TIPS or ET.There was no significant difference in overall mortality and 30-day or 6-week survival among three interventions.Compared with TIPS and ET,separately,surgical portosystemic shunts were both associated with a lower bleeding-related mortality(RR=0.07,95%CI=0.01–0.32;P<0.001;RR=0.17,95%CI=0.06–0.51,P<0.005)and rate of variceal re-bleeding(RR=0.23,95%CI=0.10–0.51,P<0.001;RR=0.10,95%CI=0.04–0.24,P<0.001),without a significant difference in the rate of postoperative hepatic encephalopathy(RR=0.52,95%CI=0.25–1.00,P=0.14;RR=1.09,95%CI=0.59–2.01,P=0.78).TIPS showed a trend toward lower variceal re-bleeding(RR=0.46,95%CI=0.36–0.58,P<0.001),but a higher incidence of hepatic encephalopathy than ET(RR=1.78,95%CI=1.34–2.36,P<0.001).Conclusions:The overall analysis revealed that there seem to be no short-term and long-term survival advantage,but surgical portosystemic shunts are with the lowest bleeding-related mortality among the three therapies.Surgical portosystemic shunts may be the most effective without an increased risk of hepatic encephalopathy and TIPS is superior to ET but at the cost of a higher incidence of hepatic encephalopathy.However,some of findings should be interpreted with caution due to the lower level of evidence and the existence of significant heterogeneity.
